库欣病的分子机制及靶向药物  

Molecular mechanisms of Cushing＇s disease and targeted drug

作　　者：辅容 卢琳[1] 龚凤英[1] 潘慧[1] 朱慧娟[1] 陆召麟[1] 

机构地区：[1]中国医学科学院北京协和医学院北京协和医院内分泌科国家卫生和计划生育委员会内分泌重点实验室,北京100730

出　　处：《国际内分泌代谢杂志》2016年第6期400-403,共4页International Journal of Endocrinology and Metabolism

基　　金：中华医学会临床医学科研专项资金-下丘脑垂体研究项目（13050940479）;国家临床重点专科基金（WBYZ2011-873）

摘　　要：由垂体瘤分泌过多的促肾上腺皮质激素导致的库欣综合征，又称为库欣病，首选治疗为手术治疗，放射治疗和药物治疗为其辅助治疗，但疗效均有限。近年来关于库欣病发病机制的研究集中于调控细胞增殖的异常蛋白表达和调控激素分泌的异常信号转导，靶点主要为表皮生长因子受体（EGFR）、细胞周期蛋白E（CDK2／CyclinE）和热休克蛋白90（HSP90），相应的靶向药物吉非替尼、roscovitine和水飞蓟素均能有效减小肿瘤体积，降低促肾上腺皮质激素水平。Cushing＇s disease, also called Cushing＇s syndrome is due to excessive secretion of adrenoeorticotropin hormone （ACTH） caused by pituitary adenoma. Surgery is recommended as the first-line therapy, while radiotherapy and medicine are adjunctive therapies. But effects of these therapies are limited. Recently, the studies on the pathogenesis of Cushing＇sdisease have focused on the abnormal protein expres- sions of cell proliferation and dysregulated signal transduetions of hormone secretion. Targets includes epider- mal growth factor receptor, eyelin-dependent kinase 2/Cyclin E and heat-shock protein 90. Corresponding targeted drugs such as gefitinih, roscovitine, silibinin are proven to be effective to reduce the volume of the tumor and the level of ACTH.

关 键 词：促肾上腺皮质激素分泌垂体腺瘤 靶向治疗 表皮生长因子 细胞周期蛋白依赖激酶2 热休克蛋白90 

分 类 号：R979.1[医药卫生—药品]